MASLD and Its Comorbidities: From Epidemiology to Future Therapeutic Perspectives
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 9 May 2025 | Viewed by 84
Special Issue Editor
2. Diabetes, Nutrition and Metabolic Diseases Outpatient Unit, Emergency County Clinical Hospital, 540136 Târgu Mureş, Romania
Interests: diabetes mellitus; beta cell; MASLD; fat; leptin
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease worldwide, currently affecting over 30% of the adult population. It has lately drawn increasing attention due to its prevalence, increased risk of hepatic and extrahepatic outcomes, and its intricate relationships with other metabolic disorders.
MASLD is part of a multisystem disease with systemic insulin resistance and associated metabolic dysfunctions at its core, which play an important role in the pathogenesis of MASLD and its comorbidities/complications. The association of MASLD with the other metabolic diseases (i.e., type 2 diabetes, obesity, dyslipidemia) significantly increases the risk of extrahepatic and liver‐related outcomes, including malignancy (advanced fibrosis/cirrhosis, hepatocellular carcinoma).
A better understanding of its pathogenetic mechanisms is essential for the prevention of progression towards the more advanced stages of this disease and improved therapeutic interventions. In addition, the changes of terminology and diagnostic criteria of the metabolic liver disease from NAFLD to MAFLD and then MASLD require the reappraisal of evidence, starting from epidemiological data to associations with the risks of developing hepatic and extrahepatic complications and, eventually, to the efficacy of various therapies.
This Dual-Section Special Issue will explore a broader range of MASLD-related topics, beginning from epidemiology and pathogenetic mechanisms, including those associated with higher risks of complications, to therapy and patient outcomes, aiming to better outline the MASLD characteristics and the relationship between MASLD and its comorbidities/complications.
This Special Issue will focus on patient outcomes, disease management strategies, and the translation of basic science discoveries into clinical practice. It will also include papers related to clinical trials, observational studies, innovative treatments, diagnostic techniques, and healthcare policy implications.
Prof. Dr. Simona Cernea
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MASLD and comorbidities/complications
- diagnostic techniques and biomarkers
- clinical trials
- innovative therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
